Confirmatory interleukin-1 receptor antagonist trial in severe sepsis
- 1 July 1997
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Critical Care Medicine
- Vol. 25 (7), 1115-1124
- https://doi.org/10.1097/00003246-199707000-00010
Abstract
SCOPUS: re.jinfo:eu-repo/semantics/publisheKeywords
This publication has 25 references indexed in Scilit:
- Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humansCytokine, 1992
- Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia.JCI Insight, 1992
- Interleukin 1 receptor antagonist. A new member of the interleukin 1 family.JCI Insight, 1991
- Interleukin-1 and interleukin-1 antagonismBlood, 1991
- A specific receptor antagonist for interleukin 1 prevents Escherichia coli ‐induced shock in rabbitsThe FASEB Journal, 1991
- Interleukin-1 receptor antagonist reduces mortality from endotoxin shockNature, 1990
- Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist.JCI Insight, 1990
- Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonistNature, 1990
- Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitorNature, 1990
- Interleukin 1 potentiates the lethal effect of tumor necrosis factor alpha/cachectin in mice.The Journal of Experimental Medicine, 1988